Stockscreener 앱 받기
1.43
3.18%
-0.04
Alx Oncology Holdings Inc 주식(ALXO)의 최신 뉴스
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Jefferies reiterates Buy rating on ALX Oncology stock, sees potential in cancer programs - Investing.com Canada
Can ALX Oncology Holdings Inc. hit a new high this month2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What analyst consensus says on ALX Oncology Holdings Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Will ALX Oncology Holdings Inc. stock outperform Dow Jones index2025 Fundamental Recap & Accurate Entry/Exit Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth buildingVolume Spike & Expert Curated Trade Setups - newser.com
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsEntry Point & Consistent Growth Equity Picks - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - Markets Financial Content
ALXO: Two high-value oncology programs advance toward key 2025 data with strong financial support - TradingView
Published on: 2025-11-19 06:30:37 - newser.com
Published on: 2025-11-19 06:25:55 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Will ALX Oncology Holdings Inc. stock deliver long term returnsCEO Change & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-18 23:37:11 - newser.com
Analyzing ALX Oncology Holdings Inc. with risk reward ratio charts2025 Trading Recap & Daily Growth Stock Tips - newser.com
Published on: 2025-11-18 12:31:34 - newser.com
ALX Oncology to Present at Upcoming Investor Conferences - The Manila Times
Published on: 2025-11-18 00:39:17 - newser.com
Statistical indicators supporting ALX Oncology Holdings Inc.’s strengthQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Will ALX Oncology Holdings Inc. outperform the marketJuly 2025 Catalysts & Community Verified Swing Trade Signals - newser.com
0.56%
1.23%
자본화:
|
볼륨(24시간):